Paper Information

Journal:   ADVANCED PHARMACEUTICAL BULLETIN   2013 , Volume 3 , Number 2; Page(s) 249 To 255.
 
Paper: 

GENE THERAPY, EARLY PROMISES, SUBSEQUENT PROBLEMS, AND RECENT BREAKTHROUGHS

 
 
Author(s):  RAZI SOOFIYANI SAEIDEH, BARADARAN BEHZAD*, LOTFIPOUR FARZANEH, KAZEMI TOHID, MOHAMMADNEJAD LEILA
 
* FACULTY OF MEDICINE, IMMUNOLOGY RESEARCH CENTER, TABRIZ UNIVERSITY OF MEDICAL SCIENCES, TABRIZ, IRAN
 
Abstract: 

Gene therapy is one of the most attractive fields in medicine. The concept of gene delivery to tissues for clinical applications has been discussed around half a century, but scientist’s ability to manipulate genetic material via recombinant DNA technology made this purpose to reality. Various approaches, such as viral and non-viral vectors and physical methods, have been developed to make gene delivery safer and more efficient. While gene therapy initially conceived as a way to treat life-threatening disorders (inborn errors, cancers) refractory to conventional treatment, to date gene therapy is considered for many non–life-threatening conditions including those adversely influence on a patient’s quality of life. Gene therapy has made significant progress, including tangible success, although much slower than was initially predicted. Although, gene therapies still at a fairly primitive stage, it is firmly science based. There is justifiable hope that with enhanced pathobiological understanding and biotechnological improvements, gene therapy will be a standard part of clinical practice within 20 years.

 
Keyword(s): GENE THERAPY, RECOMBINANT DNA TECHNOLOGY, VIRAL VECTORS, NON-VIRAL VECTORS
 
References: 
  • ندارد
 
  pdf-File tarjomyar Yearly Visit 67
 
Latest on Blog
Enter SID Blog